Joshua Hunsberger

Dr. Joshua Hunsberger


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Bio-Design and Manufacturing
Verified
Journal Article
Closed access
PDF file
DLDiana Lim
Diana Lim
EREric S. Renteria
Eric S. Renteria
DSDrake S. Sime
Drake S. Sime
YJYoung Min Ju
Young Min Ju
JKJi Hyun Kim
Ji Hyun Kim
JYJames Yoo
James Yoo

15 July 2018 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
JHJoshua Hunsberger
Joshua Hunsberger
TSThomas Shupe
Thomas Shupe
AAAnthony Atala
Anthony Atala
Regenerative medicine is poised to become a significant industry within the medical field. As such, the development of strategies and technologies for standardized and automated regenerative medicine clinical manufacturing has become a priority. An industry‐driven roadmap toward industrial scale clinical manufacturing was developed over a 3‐year period by a consortium of companies with significant investment in the field of regenerative medicine. Additionally, this same group identified critical roadblocks that stand in the way of advanced, large‐scale regenerative medicine clinical manufacturing. This perspective article details efforts to reach a consensus among industry stakeholders on the shortest pathway for providing access to regenerative medicine therapies for those in need, both within the United States and around the world. Stem Cells Translational Medicine 2018;7:564–568

15 August 2015 in Stem Cells and Development
Verified
Journal Article
Closed access
JHJoshua Hunsberger
Joshua Hunsberger
AEAnastasia G. Efthymiou
Anastasia G. Efthymiou
NMNasir Malik
Nasir Malik
MBMamta Behl
Mamta Behl
IMIvy L. Mead
Ivy L. Mead
MRMahendra Rao
Mahendra Rao
There is great need to develop more predictive drug discovery tools to identify new therapies to treat diseases of the central nervous system (CNS). Current nonpluripotent stem cell-based models often utilize non-CNS immortalized cell lines and do not enable the development of personalized models of disease. In this review, we discuss why in vitro models are necessary for translational research and outline the unique advantages of induced pluripotent stem cell (iPSC)-based models over those of current systems. We suggest that iPSC-based models can be patient specific and isogenic lines can be differentiated into many neural cell types for detailed comparisons. iPSC-derived cells can be combined to form small organoids, or large panels of lines can be developed that enable new forms of analysis. iPSC and embryonic stem cell-derived cells can be readily engineered to develop reporters for lineage studies or mechanism of action experiments further extending the utility of iPSC-based systems. We conclude by describing novel technologies that include strategies for the development of diversity panels, novel genomic engineering tools, new three-dimensional organoid systems, and modified high-content screens that may bring toxicology into the 21st century. The strategic integration of these technologies with the advantages of iPSC-derived cell technology, we believe, will be a paradigm shift for toxicology and drug discovery efforts.

14 April 2016 in Current Stem Cell Reports
Verified
Journal Article
Closed access
PDF file
JHJoshua Hunsberger
Joshua Hunsberger
JNJosh Neubert
Josh Neubert
JWJason A. Wertheim
Jason A. Wertheim
JAJulie Allickson
Julie Allickson
Anthony AtalaAnthony Atala
Anthony Atala

28 March 2020 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
JHJoshua Hunsberger
Joshua Hunsberger
CSCarl Simon
Carl Simon
CZClaudia Zylberberg
Claudia Zylberberg
PRPreveen Ramamoorthy
Preveen Ramamoorthy
TTThomas Tubon
Thomas Tubon
CMCameron Miller
Cameron Miller
The Regenerative Medicine Manufacturing Society (RMMS) is the first and only professional society dedicated toward advancing manufacturing solutions for the field of regenerative medicine. RMMS's vision is to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. Our mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by working with private and public stakeholders. We aim to accomplish our mission through outreach and education programs and securing grants for public-private collaborations in regenerative medicine manufacturing. This perspective will cover four impact areas that the society's leadership team has identified as critical: (a) cell manufacturing and scale-up/out, respectively, for allogeneic and autologous cell therapies, (b) standards for regenerative medicine, (c) 3D bioprinting, and (d) artificial intelligence-enabled automation. In addition to covering these areas and ways in which the society intends to advance the field in a collaborative nature, we will also discuss education and training. Education and training is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, and growing the workforce in the rapidly expanding sector of regenerative medicine. Significance statement The Regenerative Medicine Manufacturing Society highlights focus areas to advance the field in a collaborative nature through working groups. These focus areas include cell manufacturing, standards for regenerative medicine, 3D bioprinting, and artificial intelligence-enabled automation. These working groups will help disseminate this knowledge through future publications, as well as by identifying and developing education and training programs. Education and training programs can disseminate knowledge on current challenges and new technology innovations, as well as train the next generation workforce that will assist in making therapies the next standard of care.

27 August 2020 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
AAAnthony Atala
Anthony Atala
AHAlicia Henn
Alicia Henn
MLMartha Lundberg
Martha Lundberg
TATaby Ahsan
Taby Ahsan
JGJordan Greenberg
Jordan Greenberg
JHJoshua Hunsberger
Joshua Hunsberger
This perspective from a Regenerative Medicine Manufacturing Society working group highlights regenerative medicine therapeutic opportunities for fighting COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses and how regenerative medicine is poised to deliver new therapeutic opportunities to battle COVID-19. We describe animal models that depict the mechanism of action for COVID-19 and that may help identify new treatments. Additionally, organoid platforms that can recapitulate some of the physiological properties of human organ systems, such as the lungs and the heart, are discussed as potential platforms that may prove useful in rapidly screening new drugs and identifying at-risk patients. This article critically evaluates some of the promising regenerative medicine-based therapies for treating COVID-19 and presents some of the collective technologies and resources that the scientific community currently has available to confront this pandemic.